Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours
- 11 January 2006
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (4) , 428-432
Abstract
Purpose In patients with neurofibromatosis type-1 (NF1) and malignant peripheral nerve sheath tumours (MPNSTs), survival rates are low and time to death is often less than 2 years. However, there are patients with a more favourable prognosis who develop metastases rather late or not at all. Since histopathology and tumour grading are not well correlated with prognosis, we aimed to evaluate the potential of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) for prediction of patient outcome in MPNST. Methods FDG PET was performed in 16 patients with NF1 and MPNSTs. Standardised uptake values (SUVs) were calculated for each tumour and correlated to tumour grade and patient outcome in terms of survival or death. Results Three patients with tumour grade II had an SUV 3. Only one of these patients is still alive after 20 months; the remaining 12 died within 4–33 months. SUV predicted long-term survival with an accuracy of 94%, compared with 69% for tumour grade. In Kaplan-Meier survival analysis, patients with an SUV >3 had a significantly shorter mean survival time, 13 months, than patients with an SUV <3, in whom the mean survival time was 52 months. Tumour grading did not reveal differences in survival time (15 vs 12 months). Conclusion Tumour SUV obtained by FDG PET was a significant parameter for prediction of survival in NF1 patients with MPNSTs while histopathological tumour grading did not predict outcome.Keywords
This publication has 22 references indexed in Scilit:
- MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1Neuroradiology, 2006
- FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case reportAnnals of Nuclear Medicine, 2005
- Prevalence of Neurofibromatosis 1 in German Children at Elementary School EnrollmentArchives of Dermatology, 2005
- FDG PET imaging for grading and prediction of outcome in chondrosarcoma patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumoursEuropean Journal of Surgical Oncology, 2003
- Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Standardized Uptake Value of 2-[18F] Fluoro-2-Deoxy-D-Glucose in Predicting Outcome in Head and Neck Carcinomas Treated by Radiotherapy With or Without ChemotherapyJournal of Clinical Oncology, 2002
- Mortality in Neurofibromatosis 1: An Analysis Using U.S. Death CertificatesThe American Journal of Human Genetics, 2001
- Das histologische Erscheinungsbild bei Lokalrezidiven von WeichgewebssarkomenDer Pathologe, 1994
- A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity.Journal of Medical Genetics, 1989